Biomerica, Inc. (BMRA): Price and Financial Metrics


Biomerica, Inc. (BMRA): $2.83

-0.13 (-4.39%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

BMRA POWR Grades

  • BMRA scores best on the Value dimension, with a Value rank ahead of 58.43% of US stocks.
  • BMRA's strongest trending metric is Momentum; it's been moving down over the last 83 days.
  • BMRA's current lowest rank is in the Momentum metric (where it is better than 4.47% of US stocks).

BMRA Stock Summary

  • With a market capitalization of $38,146,739, BIOMERICA INC has a greater market value than merely 10.75% of US stocks.
  • The ratio of debt to operating expenses for BIOMERICA INC is higher than it is for about just 16.28% of US stocks.
  • With a year-over-year growth in debt of -22.74%, BIOMERICA INC's debt growth rate surpasses just 13.57% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to BIOMERICA INC are WKME, AUPH, DMTK, ADN, and AEYE.
  • Visit BMRA's SEC page to see the company's official filings. To visit the company's web site, go to www.biomerica.com.

BMRA Valuation Summary

  • In comparison to the median Healthcare stock, BMRA's price/sales ratio is 19.05% higher, now standing at 2.5.
  • BMRA's price/sales ratio has moved down 2.2 over the prior 78 months.

Below are key valuation metrics over time for BMRA.

Stock Date P/S P/B P/E EV/EBIT
BMRA 2023-01-30 2.5 5.5 -7.1 -6.4
BMRA 2023-01-27 2.4 5.4 -7.0 -6.3
BMRA 2023-01-26 2.5 5.6 -7.3 -6.5
BMRA 2023-01-25 2.4 5.4 -7.1 -6.3
BMRA 2023-01-24 2.3 5.2 -6.8 -6.0
BMRA 2023-01-23 2.4 5.3 -6.9 -6.2

BMRA Growth Metrics

    Its year over year revenue growth rate is now at 64.86%.
  • Its 5 year net cashflow from operations growth rate is now at -343.86%.
  • The 5 year cash and equivalents growth rate now stands at 55.14%.
Over the past 52 months, BMRA's revenue has gone up $10,689,500.

The table below shows BMRA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 16.08207 -4.685806 -5.561153
2022-09-30 19.24706 -2.129682 -5.060339
2022-06-30 18.87141 -0.480532 -4.531044
2022-03-31 14.62325 2.769362 -5.244388
2021-12-31 10.59138 -0.95278 -6.97953
2021-09-30 7.317008 -3.578766 -7.33942

BMRA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BMRA has a Quality Grade of D, ranking ahead of 11.64% of graded US stocks.
  • BMRA's asset turnover comes in at 0.519 -- ranking 90th of 186 Medical Equipment stocks.
  • FONR, ECIA, and SMLR are the stocks whose asset turnover ratios are most correlated with BMRA.

The table below shows BMRA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-05-31 0.519 0.051 -0.937
2021-05-31 0.519 0.069 -0.813
2021-02-28 0.582 0.140 -0.660
2020-11-30 0.460 0.232 -0.584
2020-08-31 0.549 0.240 -0.493
2020-05-31 0.682 0.266 -0.357

BMRA Price Target

For more insight on analysts targets of BMRA, see our BMRA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $12.00 Average Broker Recommendation 1 (Strong Buy)

BMRA Stock Price Chart Interactive Chart >

Price chart for BMRA

BMRA Price/Volume Stats

Current price $2.83 52-week high $5.25
Prev. close $2.96 52-week low $2.56
Day low $2.83 Volume 39,900
Day high $2.98 Avg. volume 30,408
50-day MA $3.39 Dividend yield N/A
200-day MA $3.36 Market Cap 38.15M

Biomerica, Inc. (BMRA) Company Bio


Biomerica, Inc., a biomedical technology company, together with its subsidiaries, develops, patents, manufactures, and markets diagnostic and therapeutic products or detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome (IBS) therapy technology and diagnostic-guided therapy that is designed to allow physicians to identify specific foods that when removed from the patient's diet can alleviate the patient's IBS symptoms; Helicobacter pylori products; and develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.


BMRA Latest News Stream


Event/Time News Detail
Loading, please wait...

BMRA Latest Social Stream


Loading social stream, please wait...

View Full BMRA Social Stream

Latest BMRA News From Around the Web

Below are the latest news stories about BIOMERICA INC that investors may wish to consider to help them evaluate BMRA as an investment opportunity.

Barnwell Industries, Inc. Reaches Cooperation and Support Agreement With its Largest Stockholders

Agrees to Reconstitute Its Board and Extend Standstill AgreementHONOLULU, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Barnwell Industries, Inc. (NYSE-American: BRN) (“Barnwell” or the “Company”) announce today that it has entered into a cooperation and support agreement (the “Agreement”) with its two largest stockholders, Alexander C. Kinzler, who beneficially owns approximately 9.3% of the Company’s outstanding common stock, and MRMP-Managers LLC, Ned L. Sherwood Revocable Trust, and Ned L. Sherwood (col

Yahoo | January 23, 2023

Biomerica Reports Financial Results for Fiscal 2023 Second Quarter Ended November 30, 2022

InFoods® IBS Data Receives American College of Gastroenterology Presidential Award (ACG) Following Presentation at Annual Scientific Meeting Trial Data Shows InFoods® IBS Treatment Diet Significantly Improved Several IBS Symptoms Including Abdominal Pain Intensity (API): In Some Cases Better Than Certain Currently Marketed Drugs Launch of InFoods® IBS Lab Developed Test Expected in Fiscal 3Q Amazon Now Fulfills Sales of Aware® Breast Self Exam and EZ Detect™ Colon Disease Tests IRVINE, Calif., J

Yahoo | January 13, 2023

Biomerica Appoints Mayo Clinic Gastroenterologist, Dr. Brian E. Lacy, to the Company’s Scientific Advisory Board

Dr. Lacy is the former co-Editor in Chief of the American Journal of Gastroenterology, the former Editor in Chief of Clinical and Translational Gastroenterology, and has served as the co-Chairman for the Rome IV Committee on Functional Bowel Disorders. Dr. Lacy has authored over 225 peer reviewed articles IRVINE, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) appointed prominent physician and key opinion leader Brian E. Lacy, M.D., Ph.D., a board-certifi

Yahoo | January 10, 2023

Biomerica Receives KFDA and Ministry of Health Approval for Colorectal Screening and Breast Screening Tests in Saudi Arabia and UAE

Expands Commercialization Efforts in Areas with High Unmet NeedsIRVINE, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) received clearance from the Kingdom of Saudi Arabia Food and Drug Administration (KFDA), and the United Arab Emirates (UAE) Ministry of Health and Prevention (MOHAP) for the EZ Detect™ Colon Disease test and the Aware® Breast Self Exam device. The Company is working with distribution partners to launch the products in these countries and

Yahoo | December 8, 2022

We Think Shareholders May Consider Being More Generous With Biomerica, Inc.'s (NASDAQ:BMRA) CEO Compensation Package

Shareholders will be pleased by the robust performance of Biomerica, Inc. ( NASDAQ:BMRA ) recently and this will be...

Yahoo | December 1, 2022

Read More 'BMRA' Stories Here

BMRA Price Returns

1-mo -15.77%
3-mo -6.91%
6-mo -7.21%
1-year -33.57%
3-year -7.83%
5-year -26.30%
YTD -15.52%
2022 -13.88%
2021 -21.89%
2020 64.68%
2019 77.88%
2018 -54.55%

Continue Researching BMRA

Here are a few links from around the web to help you further your research on Biomerica Inc's stock as an investment opportunity:

Biomerica Inc (BMRA) Stock Price | Nasdaq
Biomerica Inc (BMRA) Stock Quote, History and News - Yahoo Finance
Biomerica Inc (BMRA) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.3932 seconds.